These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 12582944)
1. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Stark AM; Hugo HH; Witzel P; Mihajlovic Z; Mehdorn HM Zentralbl Neurochir; 2003; 64(1):30-6. PubMed ID: 12582944 [TBL] [Abstract][Full Text] [Related]
2. p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. Stark AM; Witzel P; Strege RJ; Hugo HH; Mehdorn HM J Neurol Neurosurg Psychiatry; 2003 Jun; 74(6):779-83. PubMed ID: 12754350 [TBL] [Abstract][Full Text] [Related]
3. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374 [TBL] [Abstract][Full Text] [Related]
4. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
5. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Stark AM; Doukas A; Hugo HH; Mehdorn HM Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108 [TBL] [Abstract][Full Text] [Related]
6. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045 [TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280 [TBL] [Abstract][Full Text] [Related]
9. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line. Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T Anticancer Res; 2001; 21(1A):189-95. PubMed ID: 11299733 [TBL] [Abstract][Full Text] [Related]
11. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation]. Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244 [TBL] [Abstract][Full Text] [Related]
12. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Ganigi PM; Santosh V; Anandh B; Chandramouli BA; Sastry Kolluri VR Pediatr Neurosurg; 2005; 41(6):292-9. PubMed ID: 16293948 [TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer. Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659 [TBL] [Abstract][Full Text] [Related]
14. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. Rau B; Sturm I; Lage H; Berger S; Schneider U; Hauptmann S; Wust P; Riess H; Schlag PM; Dörken B; Daniel PT J Clin Oncol; 2003 Sep; 21(18):3391-401. PubMed ID: 12885834 [TBL] [Abstract][Full Text] [Related]
15. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Giarnieri E; Mancini R; Pisani T; Alderisio M; Vecchione A Clin Cancer Res; 2000 Sep; 6(9):3600-6. PubMed ID: 10999751 [TBL] [Abstract][Full Text] [Related]
16. p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Xinarianos G; Liloglou T; Prime W; Sourvinos G; Karachristos A; Gosney JR; Spandidos DA; Field JK Int J Cancer; 2002 Sep; 101(3):248-52. PubMed ID: 12209975 [TBL] [Abstract][Full Text] [Related]
17. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498 [TBL] [Abstract][Full Text] [Related]
19. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Halatsch ME; Schmidt U; Unterberg A; Vougioukas VI Anticancer Res; 2006; 26(6B):4191-4. PubMed ID: 17201132 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Layfield LJ; Willmore C; Tripp S; Jones C; Jensen RL Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):91-6. PubMed ID: 16540738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]